首页 | 本学科首页   官方微博 | 高级检索  
     


Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2
Authors:Abhisek Dwivedy  Richard Mariadasse  Mohammed Ahmad  Sayan Chakraborty  Deepsikha Kar  Satish Tiwari  Sankar Bhattacharyya  Sudipta Sonar  Shailendra Mani  Prafullakumar Tailor  Tanmay Majumdar  Jeyaraman Jeyakanthan  Bichitra Kumar Biswal
Affiliation:1. National Institute of Immunology, New Delhi, India ; 2. Department of Bioinformatics, Alagappa University, Tamil Nadu, India ; 3. Translational Health Science and Technology Institute, Faridabad, India ; Icahn School of Medicine at Mount Sinai, UNITED STATES
Abstract:Apart from the canonical fingers, palm and thumb domains, the RNA dependent RNA polymerases (RdRp) from the viral order Nidovirales possess two additional domains. Of these, the function of the Nidovirus RdRp associated nucleotidyl transferase domain (NiRAN) remains unanswered. The elucidation of the 3D structure of RdRp from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), provided the first ever insights into the domain organisation and possible functional characteristics of the NiRAN domain. Using in silico tools, we predict that the NiRAN domain assumes a kinase or phosphotransferase like fold and binds nucleoside triphosphates at its proposed active site. Additionally, using molecular docking we have predicted the binding of three widely used kinase inhibitors and five well characterized anti-microbial compounds at the NiRAN domain active site along with their drug-likeliness. For the first time ever, using basic biochemical tools, this study shows the presence of a kinase like activity exhibited by the SARS-CoV-2 RdRp. Interestingly, a well-known kinase inhibitor- Sorafenib showed a significant inhibition and dampened viral load in SARS-CoV-2 infected cells. In line with the current global COVID-19 pandemic urgency and the emergence of newer strains with significantly higher infectivity, this study provides a new anti-SARS-CoV-2 drug target and potential lead compounds for drug repurposing against SARS-CoV-2.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号